FDA Finalizes Heart Safety Labels for Drugs – QTc Gets the Nod
Published Date: 12/3/2025
Notice
Summary
The FDA just released new guidance to help drug makers include important heart safety info (QTc interval) in their prescription drug and biological product labels. This update affects companies making non-heart rhythm drugs and helps them show this info clearly and correctly. The guidance is final as of December 3, 2025, so companies should start updating labels soon to stay on track and avoid delays or extra costs.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
QTc Safety Info Added to Patient Labels
If you take a prescription drug or biological product that is not a heart-rhythm (antiarrhythmic) medicine, FDA's final guidance published December 3, 2025 recommends including clinically relevant heart rate–corrected QT (QTc) interval prolongation information in product labeling. The guidance specifically adds recommendations for including QTc information in FDA‑approved patient labeling and for updating QTc information in currently‑approved labeling.
Early QTc Assessment in Drug Development
The guidance recommends that applicants for most non‑antiarrhythmic drugs with systemic bioavailability assess effects on cardiac repolarization early in clinical development, including a clinical electrocardiographic (ECG) evaluation. The guidance states the QTc assessment in early development may inform the frequency and continuation of ECG monitoring in late‑phase clinical trials.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2025-21797 — Combined Notice of Filings
Several natural gas companies have filed requests to update their pipeline rates and agreements, with most changes starting January 1, 2026. These updates could affect how much customers pay for gas transportation and how companies manage fuel use. If you want to share your thoughts, you have until early December to comment before the new rates kick in.
Next: 2025-21799 — Florida Gas Transmission Company, LLC; Notice of Request Under Blanket Authorization and Establishing Intervention and Protest Deadline
Florida Gas Transmission Company wants to upgrade its natural gas pipeline in parts of Mississippi, Alabama, and Florida to move more gas—up to 170,000 MMBtu per day! This $67.5 million project will help meet growing energy needs in the South Central Alabama area. If you’re interested, you’ve got until the protest deadline to speak up or get involved.